William R Schelman

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. doi request reprint A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
    William R Schelman
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI, 53792, USA
    Invest New Drugs 32:295-302. 2014
  2. doi request reprint A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R Schelman
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K6 568 CSC, Madison, WI, 53792, USA
    Invest New Drugs 31:1539-46. 2013
  3. doi request reprint A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
    William Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:727-33. 2008
  4. pmc A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    William R Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6 534 CSC, Madison, WI 53792, USA
    Invest New Drugs 29:118-25. 2011
  5. pmc The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
    Brian S Choi
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI, 53792, USA
    Cancer Chemother Pharmacol 66:973-80. 2010
  6. pmc A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors
    William R Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6 568, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 63:1147-56. 2009
  7. doi request reprint A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study
    Noelle K Loconte
    University of Wisconsin Carbone Cancer Center and the University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6 548 CSC, Madison, WI 53792, USA
    Invest New Drugs 31:943-8. 2013
  8. pmc Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
  9. pmc A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
    Tabraiz A Mohammed
    D O, M S, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Oncologist 16:835-43. 2011
  10. doi request reprint Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
    Jill M Kolesar
    University of Wisconsin Carbone Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 72:661-7. 2013

Collaborators

Detail Information

Publications13

  1. doi request reprint A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
    William R Schelman
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI, 53792, USA
    Invest New Drugs 32:295-302. 2014
    ..Anti-tumor activity was observed in a variety of cancers including ES-SCLC, supporting further investigation with BH-3 mimetics in combination with standard chemotherapy for ES-SCLC. ..
  2. doi request reprint A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R Schelman
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K6 568 CSC, Madison, WI, 53792, USA
    Invest New Drugs 31:1539-46. 2013
    ..A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors...
  3. doi request reprint A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
    William Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:727-33. 2008
    ..We conducted a phase I trial to assess the maximum tolerated dose, dose limiting toxicity (DLT) and antitumor activity of gemcitabine and patupilone...
  4. pmc A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    William R Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6 534 CSC, Madison, WI 53792, USA
    Invest New Drugs 29:118-25. 2011
    ..To assess the maximum well-tolerated dose (MWTD), dose limiting toxicity (DLT), pharmacokinetics (PK) and pharmacodynamics of zibotentan, a novel specific endothelin-A receptor antagonist, in patients with metastatic prostate cancer...
  5. pmc The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
    Brian S Choi
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI, 53792, USA
    Cancer Chemother Pharmacol 66:973-80. 2010
    ..This study was conducted to determine the toxicity and antitumor activity of 3-AP with irinotecan. Correlative studies included pharmacokinetics and the effects of ABCB1 and UGT1A1 polymorphisms...
  6. pmc A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors
    William R Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6 568, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 63:1147-56. 2009
    ..To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics and antitumor activity of Triapine administered in combination with doxorubicin...
  7. doi request reprint A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study
    Noelle K Loconte
    University of Wisconsin Carbone Cancer Center and the University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6 548 CSC, Madison, WI 53792, USA
    Invest New Drugs 31:943-8. 2013
    ..The recommended phase II dose of sorafenib in combination with 2DOC is 200 mg BID. There were infrequent grade 3 toxicities, most evident with sorafenib at 400 mg BID...
  8. pmc Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
    ..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine...
  9. pmc A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
    Tabraiz A Mohammed
    D O, M S, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Oncologist 16:835-43. 2011
    ..Thus, this study aimed to evaluate the role of VPA in treating NETs and to determine whether VPA induced the Notch signaling pathway signaling in vivo...
  10. doi request reprint Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
    Jill M Kolesar
    University of Wisconsin Carbone Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 72:661-7. 2013
    ..Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to cell cycle arrest and apoptosis...
  11. pmc Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine
    Jill M Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Madison, 600 Highland Avenue, Room K4 554, Madison, WI 53792, USA
    J Inorg Biochem 102:693-8. 2008
    ..A potential source for the increase in the heme signal is cytochrome c released from the mitochondria. These results provide valuable insight into the in vivo mechanism of action of Triapine...
  12. doi request reprint A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors
    Dustin A Deming
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI, 53792, USA
    Invest New Drugs 32:323-9. 2014
    ..3 mg/m(2) IV on days 1, 4, 8, and 11 of a 21 day cycle. Tolerability was not improved with the intermittent dosing schedule of vorinostat when compared to continuous dosing. ..
  13. pmc A preclinical and clinical study of lithium in low-grade neuroendocrine tumors
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Oncologist 16:452-7. 2011
    ..Use of lithium chloride in murine models suppressed carcinoid cell growth, reduced GSK-3β levels, and reduced expression of chromogranin A. This study assessed the efficacy of lithium chloride in patients with NETs...